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                                      ABSTRACT 
Genome wide analysis reveals that only 2% of the genome is translated which gives the 
functional protein product. The remaining 98% do not code for any proteins and 
transcribed as non-coding RNAs (ncRNAs). These ncRNAs are involved in diverse 
biological processes. When these are deregulated, they cause cancer. microRNA 
(miRNA), a small ncRNA has been reported to be involved in cancer, but recently long 
non-coding RNAs (lncRNAs) are also emerged to be playing a role in cancers. LncRNAs 
are dysregulated in various types of cancer which includes breast, gastric, hepatocellular 
carcinoma etc. In this work, we considered an lncRNA, HULC (highly upregulated in 
liver cancer) to study its expression in breast cancer (which was not reported earlier) 
followed by studying its interaction with a miRNA, hsa-miR-30a-3p. From our qRT-PCR 
analysis, it is found that HULC is up-regulated and miRNA is down-regulated in breast 
cancer cell line, MDA-MB-231. Observing this inverse correlation in their expression 
followed by finding miRNA target sites within HULC, it was hypothesized that down-
regulation of hsa-miR-30a-3p might be leading to the up-regulation of HULC in breast 
cancer. This reports a case where one small ncRNA regulate an lncRNA which might 
have implications in breast cancer. 
 
Key Words: microRNA, lncRNA, RNA-seq, microarray, breast cancer 
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INTRODUCTION 
A hundred years ago only few people were died of cancer. However, now cancer has 
uncountable bad impacts on our health. This has unfortunately become a familiar occurrence 
and is counted as one of the ten leading causes of death in India. This might be due to day by 
day exponential rise in environmental toxins from foods, water and air which has sadly 
become a part of our life. Cancer is a class of diseases characterized by uncontrolled cell 
growth forming malignant tumors, and invading nearby parts of the body. However not all 
tumors are cancerous; benign tumor do not invade normal tissues and do not spread 
throughout the body. Among several types of cancer, breast cancer is second leading cause of 
mortality (Babu et al. 2013). 
Worldwide, breast cancer is now the most frequently diagnosed cancer among women 
(Redig et al. 2013) both in the developed and developing countries. Although breast cancer is 
thought to be a disease of the developed countries, almost 50% of breast cancer cases and 
58% of deaths occur in less developed countries also. 519,000 deaths were occurred due to 
breast cancer in breast cancer, worldwide (7% of cancer deaths and almost 1% of all deaths). 
It is estimated that 1.38 million new cases were diagnosed in 2008 (23% of all cancers) and 
around 458,000 deaths have occurred due to breast cancer (Ferlay et al. 2010). In 2014, it is 
estimated that, there will be  232,670 new cases of invasive breast cancer , 62,570 new cases 
of in situ breast cancer which includes ductal carcinoma in situ (DCIS) and lobular carcinoma 
in situ (LCIS). Of those, about 83 percent will be DCIS. 40,000 breast cancer deaths will be 
occurred (Adopted from American Cancer Society). So breast cancer has a devastating effect 
on our health. 
There are several causes of breast cancer. Now-a-days, non coding RNAs (ncRNAs) play a 
major role in development and progression of breast cancer due to their regulatory functions 
in transcriptional, post-transcriptional and epigenetic events. NcRNAs are deregulated in 
number of cancer types such as breast, lung and colorectal cancer etc demonstrating their 
oncogenic role in cancer systems and has been linked in cell proliferation and migration. 
These ncRNAs include small ncRNAs (up to 200 nt in length) as well as long non coding 
RNAs (from 200 nt up to 100kb) (Gibb et al. 2011). 
Small non coding RNA includes microRNA, piRNA, and siRNA. All sncRNA when 
deregulated cause cancer. MicroRNAs have emerging role in cancer system. MicroRNAs 
(miRNAs) regulate gene expression post-transcriptionally by binding to the 3’untranslated 
(3’UTR) region of target messenger RNA (mRNAs) and inhibit the translation or induce 
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degradation of mRNAs (Bartel 2009). MicroRNAs such as miR-10b, miR-125b, miR-145, 
miR-21, miR-155, and miR-181 were revealed to be the most consistently deregulated 
miRNA in breast cancer. 
In addition to small ncRNAs like microRNAs, long non coding RNAs (lncRNAs) has been is 
emerged out recently to have potential role in cancer development. LncRNAs play 
immeasurable role in several biological processes (Martin etal, 2014) which include X 
chromosome inactivation, nuclear structure, genomic imprinting and development (Fenoglio 
et al 2013). Dysfunction of lncRNAs has been strongly associated with several human 
diseases mainly cancer which includes modulation of melanoma cell apoptosis and invasion 
by SPRY-IT1 ( Khaitan et al. 2011), promotion of bladder cancer proliferate by UCA1a, 
control of breast cancer cell apoptosis by GAS5.Deregulation of lncRNA may happen due to 
miRNA or some other agents. There is less report about lncRNA and miRNA interaction that 
includes MALAT1, which  is down regulated by miR-9 (Leucci  et al. 2013), HULC, which 
is up regulated due to miR-372 (Wang et al. 2010). 
In our present study, we endeavoured to find novel miRNA-lncRNA interactions 
which has crucial role in breast cancer. We did real time PCR for both miRNA and lncRNA 
for expression study using breast cancer cell line MDA-MB-231 and normal cell line HaCaT. 
We got lncRNA HULC from RNA seq data (which is up regulated) and miR-30a-3p from 
RNA hybrid. HULC is upregulated in liver cancer as name suggests but later on it is also over 
expressed in gastric cancer. We want to find out whether HULC is over expressed in breast 
cancer or not. So we did expression study of HULC through wet lab to see whether it shows 
the same result to that of RNA seq data. Then we did interaction study whether one non 
coding RNA regulates the other. In this study, in the absence of miRNA, lncRNA is up 
regulated and in its presence it is down-regulated. So regulation of lncRNA is dependent on 
miRNA and its down regulation due to miRNA pays a pivotal role in breast cancer. 
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REVIEW OF LITERATURE: 
Normally, when there is a requirement of more cells to the body, older cells get died and 
younger cell divide to form new cells. But sometimes when cells are not needed, cells also 
divide and this extra mass is called tumor. These tumors are of two types i.e. benign tumor 
and malignant tumor. Benign tumors do not invade the body parts where is malignant tumors 
invade the body parts and is more dangerous. This malignant tumor is called cancer. 
Cancer is a malignant tumor involving uncontrolled cell growth. More than 100 types 
of cancers are seen which includes breast cancer, skin cancer, lung cancer, colon cancer, 
prostate cancer, and lymphoma etc. Symptoms of different types of cancer vary depending 
upon the cancer type. Chemotherapy, radiation or surgery is some of the methods of treating 
cancer. Cancer is characterized by several key characteristic features which are known as 
hallmarks of cancer proposed by Hanahan and Weinberg. These are described below in figure 
1. 
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Hall marks of cancer:. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Breast cancer: 
 
 
Breast cancer is a type of cancer originating from the inner lining of milk ducts or 
the lobules that supply the ducts with milk. Cancers originating from ducts are called as ductal 
carcinomas and that from lobules are called as lobular carcinomas. Breast cancer can occur 
in human as well as other mammals. Majority of breast cancers are seen in female and rarely 
1. IMMORTALITY Normal cell have a finite life span. But 
cancer cells under goes uncontrolled 
growth and become immortal. 
    2.  PRODUCE ‘Go’ SIGNALS Normal cell wait for a Go signal to 
divide but cancer cells produce their own 
signal and continue to divide.
3. RESIST CELL DEATH Normal cell under goes self destruction 
but cancer cells don’t under goes 
apoptosis.
4. OVERRIDE ‘STOP’ SIGNALS Normal cell produce stop signal where as 
cancer cell override these signals. 
5. ANGIOGENESIS Cancer cells keep growing by producing 
new blood vessels through process called 
angiogenesis. 
6. METASTASIS Final stage of tumor progression is the 
migration and spreading of tumor 
through a process called metastasis. 
7. UNSTABLE DNA Cancer cells have severe chromosomal 
abnormalities. 
8. DEREGULATED METABOLISM For generating more energy, cancer 
cells use abnormal metabolic pathway. 
9. EVADING IMMUNE SYSTEM Weakens the immune system of the 
body. 
 Fig. (1). Hallmarks of cancer 
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in male. It is more than 100 times more common in women than in men Breast cancer 
accounts for 23% of all cancers in women. 458,503 deaths were occurred in 2008 which 
accounts for 13.7% cancer death in women.  But survival rates in the Western world are high 
that is more than 8 out of 10 women (85%) in England diagnosed with breast cancer survive 
for at least 5 years.  Survival rate in developing countries are poor due to poor prognosis. 
Breast cancer can be invasive or non-invasive. In invasive cancer breast cancer, the 
cancer spreads outside the membrane of the lobule or duct into the breast tissue. It also can 
then spread into the lymph nodes in the armpit or beyond. Non-invasive breast cancer is the 
cancer which is still inside its place of origin and has not broken out.  Invasive ductal 
carcinoma is the most common type of breast cancer 
Symptoms of breast cancer: 
According to the National Health Service, UK, women who detect any of the following signs 
or symptoms should tell their doctor: 
 Lump formation in breast. 
 Pain in the armpits or breast. 
 Redness of the skin of the breast like the skin of an orange. 
 Bleeding can occur from the tumor. 
 Rash around the nipples. 
 Swelling in one of the armpits. 
 An area of thickened tissue in a breast. 
 One of the nipples has a discharge; sometimes it may contain blood. 
 The nipple becomes sunken or inverted. 
 The size or the shape of the breast changes. 
 The nipple-skin or breast-skin may have started to peel, scale or flake 
 
 
 
6 | P a g e  
 
Causes of breast cancer: 
Body’s breast cells also die and new cells come out like that of other cells. There is always 
wear and tear. When deviation occurs from these phenomena, breast cancer occurs. 
Followings are some of the causes of breast cancer. 
• Women over 50 are more prone to breast cancer. 
• If a woman's mother or sister had the disease before menopause, this is occasionally 
associated with one of two genes linked to breast cancer. 
• Previous breast cancer. 
• Women who haven't had children, or whose first child was born after age 30. 
• Age of menstruation - starting periods at a young age (under 12 years old) 
• Women who smoke regularly are also prone to breast cancer. 
• Women with dense breast tissue. 
• Radiation treatment to the chest before the age of 30. 
• More alcohol consumption contributes to the risk of breast cancer. 
• Uses of oral contraceptives increase risks slightly. 
• Obese women who take excess caloric and fatty food. 
• Two genes BRCA1 and BRCA2 responsible for some instances of familial breast 
cancer. 
• More exposure to hormone estrogen, more breast cancer cans occur. Estrogen gives 
signal to the cells to divide, so the cell becomes abnormal in nature. 
• Deregulation of non coding genes. 
Non-coding RNAs: 
There are only ~20,000 protein coding genes which represents only <2% of the total genome 
(Stein. 2004). This fact represents that only 2% is translated and 98% is transcribed (Birney 
et al. 2007). These transcribed regions are called as non coding region. Non coding RNAs 
play a major role in developing cancer when they get deregulated. These ncRNAs include 
small non coding RNA (sncRNA) and long non coding RNA (lncRNA). SncRNA includes 
microRNA (miRNA), small interfering RNA (siRNA), piwi interacting RNA (piRNA). 
Among them miRNA is most thoroughly studied ncRNAs and has extensive role in cancer 
development. LncRNA includes promoter associated RNA, antisense RNA etc. LncRNA 
includes many functions like transcriptional and post-transcriptional regulation, subcellular 
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trafficking and organelle biogenesis.  When ncRNAs get deregulated it causes many kinds of 
cancer. 
Now-a-days non coding RNAs play a major role in development and progression of 
cancer due to their various functions in transcriptional, posttranscriptional and epigenetic 
mechanisms of gene regulation. NcRNAs has been linked in cell proliferation and migration 
in cancer system like breast; lung and colorectal cancer etc. ncRNAs are deregulated in 
number of cancer types demonstrating their oncogenic role in cancer systems. This aberrant 
expression of ncRNAs may contribute substantially to cancer development. This ncRNAs 
include small as well as long ncRNAs. Small non coding RNA like microRNAs has role in 
cancer development but recently long non coding RNA is emerged out. 
 
MicroRNAs: 
MicroRNAs (miRNAs) are an abundant class of small ncRNA govern the post-transcriptional 
gene silencing through translational repression, and decay of their target messenger RNAs 
(mRNAs) by binding to its 3’UTR (Guo H et al. 2014).  They are single-stranded RNAs 
having length 18-24nt. (Bartel  et al. 2014).They play critical roles in diverse biological 
processes in plants and as well as in animals such as embryogenesis, cell differentiation, cell 
proliferation, organogenesis, apoptosis, and tumorigenesis. The biogenesis of miRNA in plant 
and animal is different (fig-2). Intergenic miRNA genes are transcribed into primary miRNA 
(pri-miRNA) transcripts by either RNA pol.II or RNA pol.III. In animal pri-miRNA is 
cleaved into precursor miRNA (pre-miRNA) Drosha. This pre-miRNA is then exported into 
cytoplasm by exportin 5 and is cleaved by Dicer. The product which is formed by this 
cleaving is called miRNA-miRNA* duplex having length ~22-nt. One mature miRNA is then 
binds to Ago-2 protein to form the RISC complex which is used for mRNA degradation. In 
plants, instead of Drosha, Dicer like-1 (DCL-1) cleaves the pri-miRNA to miRNA-miRNA* 
duplex (Song L etal, 2007). One mature miRNA then binds to 
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miRNA targeting: 
In miRNA, 2-7nt from the 5’end is called “seed” region. This seed region is complementary 
to the 3’UTR of the target. If this region is fully complementary to the target, complete decay 
will occur. MiRNA should be positioned within the 3´ UTR at least 15 nt away from the stop 
codon and away from the center of long UTRs. The target site should be AU rich. High 
complementarity is seen in Watson-Crick (WC) base pairing.  Apart from WC base pairing 
wobble pairing is also seen but WC pairing is most efficient one. There are three types of 
target sites viz. Canonical site, marginal site, atypical site. Canonical site consists of 7mer-
A1, 7mer-M8, 8mer; marginal site contains 6mer and offset 6mer; atypical site contains 3’ 
supplementary site and 3’ complementary site (). Efficacy of targets is in order of 
8mer>7mer-M8>7mer-A1>6mer>offset 6mer. 
  Fig. (2). Biogenesis of miRNA (Mallick et al. 2011) 
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Involvement of miRNAs in cancer: 
Deregulation of miRNAs has been demonstrated in several types of human cancers (Calin, 
2004). Several which are deregulated in cancer system are described in table-1. 
Table 1. Deregulated miRNAs in cancer 
miRNA Targets Aberrant expression Roles 
miR-21 PTEN Upregulation EMT upregulation 
miR-200 
Family 
ZEB ½ Downregulation EMT upregulation 
Fig. (3). miRNA target sites (Bartel. 2009)
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miR-34a VEGF Induced 
Upregulation 
Angiogenesis 
Downregulation 
miR-10b Syndecan-1, 
HOXD-10 
Upregulation Increased 
migration/invasion 
miR-31 ITG5, 
RhoA, MMP16, 
FZD, RDX 
Upregulation Decreased 
migration/invasion 
miR-125b STARD13 Upregulation Increased 
migration/invasion 
miR-193b Upa Upregulation Increased 
migration/invasion 
miR-194 Talin-2 Upregulation Decreased 
migration/invasion (in 
HER-2 over expressing 
cells) 
miR-632 DNAJB6 Upregulation Increased 
migration/invasion 
miR-137 ERR Upregulation Decreased 
migration/invasion 
miR-224 RKIP Upregulation Increased 
migration/invasion 
miR-218 ROBO-1 Upregulation Increased 
migration/invasion 
(Adopted from Harquail et al. 2012) 
 
Long non coding RNAs: 
LncRNAs have insignificant open reading frame. It has minimum 200nt base pair length. 
Capping and polyadenylation also occurs like that of mRNA (Carninci et al. 2005).  Both 
single-stranded and double-stranded long ncRNAs are reported. Double stranded RNA is 
formed by the transcription of Sense and antisense strands of Alu repeats (Wang et al. 2008) 
but its functional consequence is still remains unclear. A possible explanation for double 
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strandedness of ncRNAs is that the double-stranded ncRNA might not bind a target molecule 
and helps in repression of the ncRNA function. LncRNAs are known to be localized in nuclei 
and some are localized both in nuclei and cytoplasm (Imamura et al. 2004). There are no such 
computational methods for the detection lncRNA. 
 
Classification of lncRNAs: 
There are five broad categories of lncRNAs such as sense, antisense, bidirectional, intronic, 
and intergenic (Ponting etal, 2009) based upon the proximity between neighbouring 
transcripts. 
 
 
Fig. (4). Types of lncRNAs 
Role of lncRNA in cancer: 
A number of dysregulated lncRNAs have been detected from Genome-wide transcriptomic 
analyses in cancer tissues (Matouk et al. 2009).  It is found that some lncRNAs promote 
abnormal cell proliferation and tumorigenesis, whereas some prevent the formation of tumor. 
The challenging thing is to define which one is cancerous and which one is not. Table-2 
shows different types of deregulated lncRNA in cancer system. 
Table 2. LncRNA in different cancer systems and its expression 
lncRNA Expression significance 
 
MALAT1 
 
Upregulation in hepatocellular carcinoma, lung cancer, breast cancer, 
pancreatic cancer, colon cancer, prostate cancer, and so on 
 
HOTAIR 
 
Upregulation in breast cancer, hepatocellular carcinoma 
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ANRIL 
 
Upregulation in prostate cancer, coronary heart disease, 
cerebrovascular disease, diabetes, melanoma, and gliomas 
 
HULC 
 
Highly expressed in hepatocellular carcinoma 
 
lincRNA-p21 
 
Downregulation in lung cancer 
 
GAS5 
 
Downregulation in breast cancer 
 
MEG3 
CRNDE 
Downregulation in pituitary adenomas 
Upregulation in Colorectal cancer and Glioma 
PTENP1 Downregulation in Prostate cancer 
 
Role of lncRNA in breast cancer: 
Breast cancer is a very familiar cancer in female but still there are many obstacles for the 
treatment of breast cancer due to lack of understanding at the molecular level. In this regard, 
RNA molecule is the best choice for detection of mechanism. This RNA molecule can 
identify a large set of unidentified or junk RNA called long non coding RNA in human breast 
cancer. LncRNAs are known to be deregulated in many kinds of cancer and helps in 
maintaining cancer cell characteristics. It is very interesting fact that some breast cancers 
respond estrogens while others dependent on growth factors. Regarding this fact, there is 
some predictions. LncRNAs (1) are principal regulators of estrogen- or growth factor-
dependent breast cancer cell (2) will indicate the type or stage of breast cancer, and (3) are 
very much  useful therapeutic targets for treatment of breast cancer. Above statements can 
helps to determine specific role of lncRNA in breast cancer and also helps in probing the 
molecular mechanism behind it. The first human long non-coding RNA is H19 gene (Rainier 
et al. 1993) which is aberrantly expressed in breast cancer (Lottin et al. 2002). LncRNA 
HOTAIR (2.2kb) expression is strongly associated with metastases of breast cancer patients, 
and expression levels correlate positively with a poor outcome (Gupta et al, 2010). HOTAIR 
helps chromatin modification. LncRNA BCYRN1 (BC 200) is highly upregulated in breast, 
ovarian, cervical, lung and other cancer (Chen et al. 1997). MALAT1, a 7kb lncRNA, has 
role in non-small cell lung cancer, (Ji et al. 2003) and is also deregulated in breast cancers 
(Guffanti et al. 2009). 
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HULC and cancer: 
HULC is an lncRNA having length 500nt. HULC refers to highly upregulated in liver cancer. 
It has been reported that HULC act as endogenous sponge and down regulates a series of 
miRNA like miR-372, miR-613 (Jiayi et al. 2010) due to its promoter activity. Repression of 
miR-372 leads to upregulation of its corresponding gene called PRKACB. Later on HULC is 
also over expressed in gastric cancer (Zhao et al. 2014). But till now it is not reported in 
breast cancer. So it will be a newer approach if it is still remain upregulated in breast cancer. 
miR-30a-3p and cancer: 
miR-30a-3p is downregulated in Hepatocellular carcinoma and it acts as a tumor suppressor 
in vitro (Wang et al. 2013). It is also down regulated in colorectal cancer (Ma et al. 2012). It 
is not reported in breast cancer yet. 
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OBJECTIVES: 
Objective 1: 
HULC, as the name suggests, found in liver cancer. We want to know whether it is 
significantly expressed in other systems like breast cancer, 
Objective 2: 
We want to explore why this lncRNA is upregulated and what is its impact on oncogenesis of 
breast cancer. 
Objective 3: 
We are curious to know whether conventional targeting or ceRNA is involved in miRNA-
lncRNA interaction is operational in breast cancer contributing to its oncogenesis. 
Objective 4: 
Microarray expression analysis for identification of differentially expressed miRNA in breast 
cancer. 
Objective 5: 
RNA seq analysis for identification of differentially expressed lncRNA in breast cancer. 
Objective 6: 
Identification of novel lncRNA–miRNA target pairs involved in breast cancer & 
experimental validation of both miRNA and lncRNA expression by RT-PCR in MDA-MB-
231 breast cancer cell lines and HaCaT control cell line. 
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MATERIALS AND METHODS: 
1.1 Data retrieval from microarray data. 
For genome wide analysis of miRNA and mRNA of normal and diseased sample gene 
expression data was taken. From Gene Expression Omnibus (GEO) database, the gene 
expression data were retrieved. GEO a public data repository and data retrieval system where 
next-generation sequencing, microarray and other forms of high-throughput functional 
genomic data are freely available, submitted by scientific community. This database supports 
MIAME-compliant data submissions. A collection of web-based interfaces and applications 
are available to provide help users query and download experiments and curated gene 
expression profiles stored in GEO. The GEO data contains raw microarray data which 
involves images that are to be converted into gene expression matrices; rows represent genes, 
columns represent various samples such as tissues or experimental conditions, and numbers 
in each cell illustrate the expression level of the particular gene in the particular sample. 
Analysis of the matrices can be further done in order to extract any biological process and its 
understanding. Platform describes the list of features on the array (e.g., cDNAs, 
oligonucleotides, etc.). There is an importance of using different platforms as because of the 
diversity of technical and analytical sources that can affect the results of an experiment. 
Therefore, a single platform may be inefficient for comparison among experiments. So, large-
scale comparison studies involving microarrays can be done using various platforms for 
optimum reproducibility measurements. 
There are 2 ways by which the GEO data may be retrieved 
• GEO data may be retrieved by querying GDS (GEO datasets), gene 
profiles and GEO accession number. 
• GEO data can be accessed directly on the web by browsing through 
datasets or GEO accessions options available with respect to individual 
platform, sample and series. Related records are intra-linked on the 
GEO sites such that one may conveniently navigate to the associated 
platform, series, and sample and GEO dataset records. 
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Fig. (5) GEO datasets 
1.2 Analysis through GEO data base: 
• Go to main page of GEO data base. 
• Type mRNA expression in breast cancer AND Homo sapiens in data sets 
option. 
• Then click on GO. 
• Then results appear which contain the list of microarray experiments. From 
that each GSE is checked for expression profile analysis having platform 
Agilent-031181 Unrestricted_Human_miRNA_V16.0_Microarray 030840 
(miRBase release 14.0 miRNA ID version),the expression is without induce of 
any drug. 
• From that GSE38867 is taken for analysis. 
• From that 5 controls (normal) and 3 tests (disease) samples were taken. To 
reduce the error triplicate should taken. 
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Table 3. Shows normal and test samples. 
CONTROL TEST 
GSM951056 GSM951062 
GSM951068 GSM951066 
GSM951048 GSM951054 
GSM951064  
GSM951060  
 
• From that, a raw file was down loaded, it was unzipped and for further analysis 
it was uploaded in GeneSpring software. 
1.3 Analysis of gene expression data: 
• Expression data is analyzed by using GeneSpring software. 
GeneSpring software 
GeneSpring is software which provides statistical tools for visualization and data 
analysis. For understanding of Transcriptomic, Metabolomics, Proteomics and NGS data 
within a biological context, GeneSpring is very useful. It also helps in expression analysis. 
This software is a key component of systems biology research, involves producing 
heterogeneous data that measure various biological entities and events such as variation in 
expression of microRNA and mRNA exon splicing, DNA structure,  proteins and 
metabolites, which helps to understand underlying mechanism of diseases. It also allows 
researchers to analyse, compare different signalling pathway. 
Other applications of GeneSpring include: 
• Gene expression analysis of microarray platforms like Affymetrix, Agilent and 
Illumina. 
• Analysis of Real-time PCR data. 
• GEO datasets. 
Data analysis using GeneSpring 
For miRNA expression analysis: 
Procedure 
• The raw data files from GEO database were downloaded as a zip file. 
• The files then were unzipped, extracted and renamed according to the convenience. 
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• Firstly, a new project was selected where many platforms came.  From that, a desired 
platform type was selected. 
• Then the name of the project was given. 
• A new experiment was set by setting experiment name and experiment type. 
• Then guided work flow was chosen as work flow type. 
• Then data is loaded and the desired technology is selected i.e. Agilent-031181 
Unrestricted_Human_miRNA_V16.0_Microarray 030840 (miRBase release 14.0 
miRNA ID version).Then files were chosen as 3 replicates i.e. Control and Test files. 
• Then by normalizing the noise signal the intensity map could be seen. 
• Then Experimental setup was done by following methods. 
¾ First experimental grouping was done by adding parameters to Average. 
¾ Then Average over replicates in condition was chosen in case of Create 
Interpretation. 
• Then quality control is done by following methods. 
¾ First a Filter Probe sets by errors was set. 
¾ Then the coefficient of variation was chosen < 50%. 
¾ Then Output views of filter were chosen. 
¾ Then the entity list was saved. 
• Then Analysis was done by following method 
¾ First Statistical Analysis was chosen. 
¾ After that Entity list was Filtered on error <50. 
¾ Then the Interpretation was chosen Average. 
¾ Condition 1 and Condition 2 for Select test. 
¾ T-test is unpaired chosen for 2 sets of data. If more than 2 sets be present 
then Anova should be chosen. 
¾ Then the p- value computation was chosen Asymptomatic. 
¾ Then the Number of permutation should be 100. 
¾ Then multiple testing corrections was chosen Benjamin Hochberg FDR. 
¾ Then in Results cut-off should be chosen ≤ 0.05 which was present by default. 
¾ Then the entity list was saved. 
• Then the Fold Change was chosen and done by following these Input parameters 
and pairing options. 
¾ The Fold change results cut-off should be >=2.0. 
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• Then Clustering was done by following methods: 
¾ First Input parameters were taken. 
¾ Then in Entity list, Fold change >=2.0 was chosen. 
• Then the Interpretation was chosen all samples. 
• The Cluster algorithm was chosen Hierarchical. 
• The Cluster was done on Conditions 
• Then the Distance metric was chosen Pearson uncentered. 
• The Linkage rule was chosen Average. 
• Then Result file was saved. 
• After that Result interpretation was done by following method 
• Then GO analysis by choosing output views. 
• Export of Fold change data was done by adopting the following method: 
¾ Entity list was exported. 
¾ Normalization of the signal values was done. 
¾ Then - miRNA was selected in selected items. 
¾ Then Interpretation of All samples was done. 
• Then it was saved as- Tab separated file (.txt) 
• Then we have to see how the control varies from test sample. 
• To see how the control varies from test sample clustering was done by using Cluster3 
and java treeview software was used. 
 
RNA-seq analysis of lncRNAs: 
The transcriptional profiling data of breast cancer was obtained from GEO database 
having the accession number GSE28866.The retrieved dataset comprised of transcriptional 
profiles for six normal breast tissue samples and six breast cancer tissue samples. We have 
used the RNAseq protocol as follow. 
 
System Specification 
The work was carried out on ProLite HP server with the below specification. 
1. Operating system: CentOS Release 6.5 (Final). 
2. Kernel-2.6.32-431.el6.x86_64 
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3. GNOME   2.28.2 
4. Hardware: Memory: 15.4 GiB 
5. Processor: Intel(R) xeon(R) CPU E5-2420 0 @ 1.90GHz 
Software Requirement: 
1. SRA tool kit 
2. FastQC 
3. FASTX 
4. SAMtools 
5. BOWTIE 
6. GeneSpring NGS 12.6 
Quality check and Filtration: 
SRA tool kit (fastq-dump) was used to convert SRA files into fastq files. The qualities 
of the raw reads were found to be reliable predicted by FastQC and the illumina adapters 
present in the reads were filtered out using FASTX. 
Command to run fastqc: 
fastqc -t  SRR191639.fastq 
Command to run fastx_clipper: 
fastx_clipper –a illumina_adapter.fasta -i SRR191639.fastq –o SRR191639_clipped.fastq 
Reference Genome Mapping: 
The filtered reads were mapped to the human reference genome (hg18) using 
BOWTIE and the aligned files were saved in sam format. 
Command to run BOWTIE: 
bowtie -q -m 1 –v 3 --sam --best --strata hg18 SRR191639_clipped.fastq - >  
SRR191639_mapped.sam 
File Format Conversion and sorting: 
SAMtools was used to convert the file into BAM format followed by sorting the reads 
in aligned files and index generation. 
Command to run SAMtools: 
samtools view  -b  -S  -o SRR191639_mapped.bam SRR191639_mapped.sam 
samtools sort SRR191639_mapped.bam SRR191639_sorted.bam 
samtools index SRR191639_sorted.bam 
Quantification and Differential Expression Analysis: 
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Transcript assembling was carried out using GeneSpring NGS 12.6 refereeing RefSeq 
as the annotated gene map. Differential expression analysis was performed using DESeq 
(Bioconductor Package) inbuilt in GeneSpring NGS 12.6. 
Retrieval of miR-30a-3p from RNAhybrid: 
All total 218 differentially expressed miRNA was taken from microarray dataset. Sequences 
of all the miRNA was retrieved from miRBase software. This data is then hybridised with 
HULC by RNAhybrid software. By doing this we got miR-30a-3p. 
RNAhybrid software: 
RNAhybrid is a tool for finding the minimum free energy hybridisation of a long (target) and 
a short RNA (query). The hybridisation is performed in a kind of domain mode, i.e. the short 
sequence is hybridised to the best fitting part of the long one. The tool is primarily meant as a 
means for microRNA target prediction. The web form of the online version of RNAhybrid 
offers a various number of options (shown below) to run RNAhyrbid successfully. 
Target RNA:  
Each of the target sequences in target file is subjected to hybridisation with each of the 
queries (which either are from the query file or is the one query given on command line; see -
q below). The sequences in the target file have to be in FASTA format, ie. one line starting 
with a > and directly followed by a name, then one or more following lines with the sequence 
itself. Each individual sequence line must not have more than 1000 characters. If no -t is 
given, either the last argument (if a -q is given) or the second last argument (if no -q is given) 
to RNAhybrid is taken as a target. 
Query RNA:  
see target RNA description 
Hit per target (-b) 
Maximal numbers of hits to show. Hit number hits with increasing minimum free energy 
(reminder: larger energies are worse) are shown, unless the -e option is usedand the energy 
cut-off has been exceeded (see -e option below) or there are no more hits. Hits may only 
overlap at dangling bases (5' or 3' unpaired end of target). 
Compact output (-c) (optional): 
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Produce compact output. For each target/query pair one line of output is generated. Each line 
is a colon (:) separated list of the following fields: target name, query name, minimum free 
energy, position in target, alignment line 1, line 2, line 3, line 4. 
Helix constraint (-f) (optional): 
Forces all structures to have a helix from position from to position to with respect to the 
query. The first base has position 1. 
We have given 2-7 bp as helix constraint. 
Maximal internal loop size (-u) (optional): 
The maximally allowed number of unpaired nucleotides in either side of an internal loop. 
Maximal bulge loop size (-v) (optional): 
The maximally allowed number of unpaired nucleotides in either side of an internal loop. 
Energy cut off (-e) (optional): 
Hits with increasing minimum free energy (reminder: larger energies are worsening) less than 
or equal to energy cut off are shown, unless the –b option is used and the number already 
reported hits has reached the maximal hit number. Hit may only overlap at dangling bases (5’ 
or 3’ unpaired end of target). 
We have given -15 as energy cut off. 
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Experimental Validations: 
Animal Cell culture: 
MDA MB 231, a human breast carcinoma cell line, was taken from National Centre for Cell 
Science (NCCS), Pune, India. Before culturing these cell lines are maintained in 20° c in 
carbon dioxide incubator. Media used for these cell cultures is DMEM. 
MDA-MB-231: 
It is breast cancer cell line. Requires DMEM medium for growth. 
HaCaT: 
It is the control cell line which also grows in DMEM media. 
 
Steps for cell culture: 
Cell thawing: 
 
1. Water was heated up to 37’c and within which the cells were plated. A vial of frozen 
cells were removed from liquid nitrogen and placed in the water bath until it was 
thawed. 
2. Outside of the vial was washed with 70% alcohol. 
3. Then the thawed cell specimen was pipetted into cell culture vessel containing growth 
medium. The vessel was swirled gently to mix the cell with the medium. 
4. Sometimes removal of DMSO is necessary for suspension cell, primary cells and 
sensitive cell types. For such cell types, the thawed cell suspension was pipetted into a 
sterile centrifuge tube containing medium. Centrifugation was done at 200g for 2 
minute. Then supernatant was aspirated and cells were resuspended into fresh 
medium. 
5. Cells were incubated overnight under their usual growth condition. 
6. In the next day, growth medium was replaced. 
Trypsinizing cells: 
Trypsinization is a technique which uses the proteolytic enzyme trypsin to detach 
adherent cells from the surface of a cell culture vessel. This procedure  is followed 
whenever the cells need to be harvested. 
7. The medium was aspirated and then discarded. 
8. The cells were washed with PBS (phosphate buffer saline). 
9. 1x trypsin EDTA was added to the solution. 
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10. Then the flask was placed in a CO2 incubator at 37’c for 1-2 min. 
11. Flask was removed from incubator and then it was tapped with palm to assist 
detachment. 
12. Once discarded the cells were then resuspended in growth medium containing serum. 
The serum inactivates trypsin activity. 
13. The cells were gently pipetted up and down for proper mixing. 
14. Then proceed as required. (e.g-with freezing, nucleic acid isolation.) 
 
 
RNA Isolation: 
The kit used for miRNA is called  mirVana  from QIAGEN. 
1. The cells were trypsinized and collected. Then it was washed with PBS and pellet was 
collected, and then was placed in ice. 
2. PBS was removed. Lysis binding solution was added if cells were 100s in number-
300 μl and if cells were 1000s in number-600 μl. Then vortexing was done vigorously 
to make homogenous lysate. 
3. 60 μl of miRNA homogenate additive was added to the cells. Then it was mixed well 
by vortexing for several times and then it was remained on ice for 10 minutes. 
4. 1 volume of acid-chloroform was added and vortexing for 30-60 sec. Centrifugation 
was done at 10,000gnto separate aqueous and organic phase. After centrifugation, the 
interphase should be compact if it is not repeat centrifugation. The aqueous phase was 
removed without disturbing the lower phase and was transferred it to a fresh tube. 
5. 1.25 volume of room temperature 100% ethanol was added to the aqueous phase. 
6. Filter cartridge was placed into one of the collection tube. Lysate ethanol was pipetted 
and mixed into the filter catridge (up to 700 μl, add step wise thereafter). 
Centrifugation was done for 15 sec at 10,000 rpm. Flow through was discarded. 
7. 700 μl of miRNA wash solution 1 was added to filter catridge. Centrifugation was 
done for 5-10 sec. Flow through was discarded. 
8. 500 μl of buffer RPE and centrifugation was done for 15sec at ≥8000×g.. Flow 
through was discarded 
9. 500 μl of buffer RPE and centrifugation was done for 2 min at >8000xg. Flow 
through was discarded at ≥8000×g. 
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10. The RNeasy spin column was placed in the new 1.5 ml collection tube. 30-50 μl 
RNasefree water was added directly to the spin column membrane. The lid was closed 
and centrifuged for 1min at ≥8000×g to elute the RNA. 
11. If the expected RNA yield is >30 μg, then step 7 was repeated using another 30-50μl 
of RNase- free water, or using the eluate from step-7. The collection tubes were 
reused from step-7. 
12. The purity and yield of RNA yield was measured by Eppendorf NanoDrop. It is a 
cuvette free spectrophotometer which eliminates the need for other sample 
containment devices and allows for clean up in seconds. It measures 1 μl samples 
with high accuracy and reproducibility. The full spectrum (220nm-750nm) 
spectrophotometer utilizes a patented sample retention technology that employs 
surface tension alone to hold the sample in place. A 1 μl sample is pipetted onto the 
end of a fiber optic cable (the receiving fiber). A second fiber optic cable (the source 
fiber) is then brought into contact with the liquid sample causing the liquid to bridge 
the gap between the fiber optic ends. The gap is controlled to both 1mm and 0.2 mm 
paths. A pulsed xenon flash lamp provides the light source and a spectrometer 
utilizing a linear CCD array is used to analyze the light after passing through the 
sample. The instrument is controlled by PC based software, and the data is logged in 
an archive file on the PC. 
cDNA synthesis: 
cDNA synthesis was carried out using SuperScript First-Strand Synthesis System for RT-
PCR by Invitrogen using oligo dT primers. 
Procedure: 
1. Each of the components were mixed and briefly centrifuged before use. 
2. For each reaction, the following in a sterile 0.2 or 0.5ml tube was combined 
Table 4. Components using in cDNA synthesis. 
Components Amount 
RNA 4 μl 
10 mM dNTP mix 1 μl 
Primer (0.5μg/μl oligo (dT)12-18 or 2μM 
gene 
specific primer) 
 
1 μl 
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DEPC treated water 2 μl 
 
4. The RNA/primer mixture at 65·c for 5 minutes was incubated, and then placed on ice 
for at least 1 minute. 
5. In a separation tube, the following 2X reaction was prepared by adding each component in 
the indicated order. 
 
 
 
Table 5. Different components used in cDNA synthesis. 
Components 1RXn 10 RXns 
10X RT buffer 2 μl 20 μl 
25mM Mgcl2 4 μl 40 μl 
0.1M DTT 2 μl 20 μl 
RNase out TM (400/ μl) 1 μl 10 Μl 
 
 
7. 9μl of the 2X reaction mixture was added to each RNA/primer mixture from step3, 
mixed gently and collected by briefly centrifuge. 
8. It was incubate at 42°c for 2 minutes. 
9. 1μl of super script TM II RT was added to each tube. 
10. It was incubate at 42°c for 50 minutes. 
11. The reaction was terminated at 70·c for 15 minutes. Chilled on ice. 
12. The reaction was collected by brief centrifugation. 1μl of RNase H was added to each 
tube and incubated for 20minutes at 37·c. The reaction was used for PCR 
immediately. 
 
Quantitative Real Time RT-PCR Analysis: 
Real-time PCR is the continuous collection of fluorescent signal from one or more 
polymerase chain reactions over a range of cycles. Quantitative RT-PCR involves the 
conversion of the fluorescent signals from each reaction into a numerical value for each 
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sample. Fluorescent marker is used which binds to the DNA. Therefore, as the number of 
gene copies increases during the reaction so the fluorescence intensity increases. This is 
advantageous because the rate of the reaction and efficiency can be seen. Intercalating 
fluorescent dyes (e.g. SYBR green) are the simplest and cheapest way to monitor a PCR in 
real-time. The SYBR green dye fluoresces only when bound to double-stranded DNA. The 
major disadvantage of using a dye such as this is the lack of specificity. 
MiRNA primer sequence was designed by us using tools like Amplifx (1.5.4) and ApEA 
plasmid editor. This sequence was ordered from SIGMA GENOSYS. All the primers were 
desalted and UV absorbance was used to assess the quality of primer synthesis. 
To perform PCR using RNA as a starting template which must first be reverse 
transcribed into cDNA in a reverse transcription (RT) reaction, where the cDNA is used as 
template for real-time PCR with gene specific primers. 
Table 6. Primer name and sequence with length 
Primer name 5’<----sequence--->3’ Length 
beta actin F 
beta actin R 
CATGTACGTTGCTATCCAGGC 
CTCCTTAATGTCACGCACGAT 
21 
21 
HULC F 
HULC R 
ATCTGCAAGCCAGGAAGAGTC 
CTTGCTTGATGCTTTGGTCTGT 
21 
22 
miR-30a-3p F GCCCTTTCAGTCGGATGTTTGCAG
 
24 
 
Quantification of HULC: 
Real-time PCR was carried out in Eppendorf Masterplex Real Time PCR. 
1. Total master mix was prepared for 3 genes; one house keeping gene, HULC, and two 
samples: HaCaT and MDA-MD-231. 
2. Following components were required for quantification. 
3. cDNA was diluted into 1:20 ratio concentration 
5. The following mixture was taken as follows for preparation 
Table 7. Components for lncRNA, HULC: 
Component Amount 
SYBR Green Mix 65 μl 
cDNA stock (cDNA: dH2O [1:20]) 39 μl 
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primer pair mix (3.25 μl each primer) 13 μl 
 
6. Master mix contains all the components except cDNA. 13 μl of water was added to the 
master mix and the mix was divided into two aliquots. 
7.  To each aliquot, forward and reverse primer (3.25 μl each) was added. This mix was again 
divided into two aliquots. 
8. Then to each reaction, 9. 75 μl of cDNA was added. 
10. Each reaction mix was divided into replicates. 
11. Then it was in RT-PCR. The experiment was set up and the following PCR program was 
made on. A copy of the setup file was saved and all PCR cycles were deleted. The threshold 
frequency taken was 33%. The cycle temperatures taken were as follows: 
 
 
Table 8. Cycle temperature and time for qRT-PCR 
STAGE TEMPERATURE 
(°C) 
TIME CYCLE 
Stage 1 95 20sec 1 
Stage 2 95 
55 
68 
15sec 
15sec 
20sec 
40 
Stage 3 95 
60 
95 
15sec 
15sec 
15sec 
1 
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Quantification of miR-30a-3p: 
All the above procedure was also same for miRNA except the following components. 
Table 9. Components for miRNA miR-30a-3p 
Component Amount 
SYBR Green Mix 65 μl 
cDNA stock (cDNA: dH2O [1:20]) 13 μl 
primer pair mix (3.25 μl each primer) 5.2 μl 
ROX 0.52 μl 
 
 
 
 
 
 
 
Fig. (6). Cycle temperature and time for qRT-PCR 
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RESULTS AND DISCUSSIONS: 
miRNA expression result from microarray analysis: 
 
 
                                            Fig. (7). Clustering of miRNA 
From this figure, different expression pattern of miRNAs were seen. Blue colour shows 
down-regulation, yellow shows normal and red colour shows up-regulation. Based upon their 
similarity in expression, miRNAs clustered together. 
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RNA-seq result: 
 
 
 
Fig. (8). Location of HULC in genomic DNA 
Above figure shows location of HULC in chromosome 6. We choose HULC for our 
experiment because it is highly expressed and yet not validated in breast cancer. 
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Fig. (9). Normalized intensity values of genes 
Before quality check each entity should be normalized to reduce the systematic variation. 
Above figure shows the expression value of different genes. 
 
RNAhybrid result: 
We took 218 miRNA for interaction with HULC. Among this, 9 miRNA was 
complementarily bind with HULC. From these 9 miRNA, miR-30a-3p was selected as it has 
complete Watson-Crick base pairing in seed region as well as in other region and energy cut 
off is also more. 
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Experimental Validations: 
RNA isolation 
• 260/280 Ratio: This ratio indicates the absorbance of DNA and RNA at 260 nm and 280 
nm, which is used to assess the purity of DNA and RNA. A ratio is expected approximately 
1.8 and generally accepted as “pure” for DNA; a ratio of approximately 2.0 is generally 
accepted as “pure” for RNA. In either case, if the ratio is significantly lower it may indicate 
the presence of phenol, protein or other contaminants that absorb strongly at or near 280 nm. 
• 260/230 Ratio: This ratio is used as a secondary measure of nucleic acid purity and 
phenolic contamination. The 260/230 values for “pure” nucleic acid are often higher than the 
respective 260/280 values. Expected 260/230 values are normally in the range of 2.0-2.2. If 
the ratio is significantly lower than expected, the presence of contaminants which absorb at 
230 nm. is indicated. 
• Here, we got following results of two samples; Sample1 has perfect ratio absorbance in 
260nm and 280 nm wavelengths where Sample2 has less value. 
• Sample1 = 870.5 μg/ml 
At (260/280) ratio = 2.07 
At (260/230) ratio = 2.01 
• Sample 2 = 828.4 μg/ml 
At (260/280) ratio = 2.07 
At (260/230) ratio = 1.69 
qRT-PCR: 
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qRT- PCR melting curve analysis was used to quantify nucleic acid, mutation detection and 
for genotype analysis. 
• The melting temperature curve for the HULC and miR-30a-3p with respect to control , β-
actin was observed. 
 
 
 
Fig. (10). Melting curve of HULC 
 
From the qRT PCR analysis of HULC, a fine melting temperature curve was observed in 
comparison to the control gene, β-actin. The melting temperature of HULC is 
85°c.  The samples of gene were taken in triplicates. Three peaks of HULC positioned at one 
place were observed. The relative quantification of HULC with respect to β-actin shows high 
expression of HULC. 
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Fig. (11). Melting curve of miR-30a-3p 
From the qRT PCR analysis of miR-30a-3p, a fine melting temperature curve was observed 
in comparison to the control gene, U6. The melting temperature of miR-30a-3p is 
81°c.  The samples of gene were taken in triplicates. Three peaks of miR-30a-3p positioned at 
one place were observed. The relative quantification miR-30a-3p of with respect to U6 shows 
high expression of miR-30a-3p. 
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CONCLUSIONS: 
Our study aimed at identification of novel lncRNA-miRNA target pairs that are hypothesized 
to play a role in breast cancer through experimental validation of selected lncRNA and 
miRNA. From miRNA microarray expression analysis, we found that the total number of 
differentially expressed miRNA in breast cancer is 197, out of which 122 are down regulated 
and 75 are up-regulated. We did RNA-seq analysis where we found a huge number of 
lncRNAs that are expressed differentially in breast cancer. From this set of differentially 
expressed lncRNAs, we selected one lncRNA, HULC. HULC was reported for the first time 
in liver cancer and was named as “highly upregulated in liver cancer” or HULC. HULC is 
over-expressed in liver cancer and gastric cancer; however it was not reported in breast 
cancer. After selecting HULC, we hybridized this lncRNA with a down-regulated miRNA 
obtained from microarray data using RNAhybrid software. It was seen that HULC has 
complementarily with 9 miRNAs. Further screening of these HULC-miRNA pairs based on 
criteria like stability, more complementarily binding lead to identification of a significant 
miRNA-HULC pair that might have crucial role in breast cancer malignancy. None of the 
members of this pair are validated in breast cancer till now. Therefore, we did experimental 
validation of both miRNA and lncRNA by RT-qPCR in MDA-MB-231 cell line. We found 
high up-regulation of HULC and down-regulation of miR-30a-3p. Upregulation of HULC 
might be due to down-regulation of hsa-miR-30a-3p which in turn might help in histone 
modification which gives its oncogenic properties. We want to confirm whether one ncRNA 
could regulate the other. 
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FUTURE PROSPECTIVES: 
It is a very challenging and interesting topic that how a ncRNA regulates another 
ncRNA. For this type of regulation, conventional way exists miRNA→RNA. But it can be 
assumed in reverse way i.e. RNA→miRNA through competitive endogenous RNA (ceRNA) 
hypothesis. If it is successful, then many hidden layers of regulation by lncRNAs will come 
into limelight and can help to understand the systems biology of malignancy. 
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